Qube Research & Technologies Ltd Grows Position in Encompass Health Corporation $EHC

Qube Research & Technologies Ltd increased its holdings in Encompass Health Corporation (NYSE:EHC) by 47.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 783,103 shares of the company’s stock after acquiring an additional 251,037 shares during the quarter. Qube Research & Technologies Ltd owned about 0.78% of Encompass Health worth $96,032,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. LPL Financial LLC lifted its holdings in shares of Encompass Health by 30.8% during the first quarter. LPL Financial LLC now owns 46,525 shares of the company’s stock valued at $4,712,000 after purchasing an additional 10,967 shares during the last quarter. US Bancorp DE increased its holdings in Encompass Health by 71.5% during the first quarter. US Bancorp DE now owns 2,367 shares of the company’s stock valued at $240,000 after buying an additional 987 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Encompass Health by 6.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 685,577 shares of the company’s stock valued at $69,435,000 after purchasing an additional 40,813 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Encompass Health by 749.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company’s stock valued at $42,000 after acquiring an additional 367 shares during the period. Finally, Townsquare Capital LLC raised its position in shares of Encompass Health by 13.2% during the 1st quarter. Townsquare Capital LLC now owns 4,467 shares of the company’s stock valued at $452,000 after purchasing an additional 521 shares during the period. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 1.5%

Shares of NYSE EHC opened at $106.37 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.76. The business has a fifty day simple moving average of $118.17 and a two-hundred day simple moving average of $119.05. The firm has a market cap of $10.70 billion, a PE ratio of 20.11, a price-to-earnings-growth ratio of 1.91 and a beta of 0.73. Encompass Health Corporation has a twelve month low of $87.85 and a twelve month high of $127.99.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. Encompass Health had a return on equity of 17.84% and a net margin of 9.33%.The business had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. Analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Friday, January 2nd will be given a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, January 2nd. Encompass Health’s dividend payout ratio is 14.37%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Weiss Ratings restated a “buy (b+)” rating on shares of Encompass Health in a research note on Wednesday, October 8th. Raymond James Financial raised shares of Encompass Health to a “strong-buy” rating in a research note on Friday, October 31st. Barclays increased their price objective on shares of Encompass Health from $141.00 to $150.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Bank of America upped their target price on shares of Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, September 10th. Finally, Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Sunday, November 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $142.86.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.